← Back to Search

Monoclonal Antibodies

Sym021 for Lymphoma

Phase 1
Waitlist Available
Led By Lillian Siu, MD, FRCPC
Research Sponsored by Symphogen A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Summary

This trial is testing how safe and tolerable three different possible treatments are for patients with cancer that has spread or cannot be removed by surgery.

Eligible Conditions
  • Cancer
  • Solid Tumors
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.
Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.
Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.
Secondary outcome measures
Area under the concentration-time curve in a dosing interval (AUC)
Clearance (CL)
Evaluation of objective response (OR) or stable disease (SD).
+6 more

Trial Design

17Treatment groups
Experimental Treatment
Group I: Sym021+Sym022+Sym023 Dose Level 5Experimental Treatment3 Interventions
Part 3, Sym021 in combination with Sym022 and Sym023
Group II: Sym021+Sym022+Sym023 Dose Level 4Experimental Treatment3 Interventions
Part 3, Sym021 in combination with Sym022 and Sym023
Group III: Sym021+Sym022+Sym023 Dose Level 3Experimental Treatment3 Interventions
Part 3, Sym021 in combination with Sym022 and Sym023
Group IV: Sym021+Sym022+Sym023 Dose Level 2Experimental Treatment3 Interventions
Part 3, Sym021 in combination with Sym022 and Sym023
Group V: Sym021+Sym022+Sym023 Dose Level 1Experimental Treatment3 Interventions
Part 3, Sym021 in combination with Sym022 and Sym023
Group VI: Sym021 Dose Level 3Experimental Treatment1 Intervention
Part 1, Sym021 monotherapy dose level 3
Group VII: Sym021 Dose Level 2Experimental Treatment1 Intervention
Part 1, Sym021 monotherapy dose level 2
Group VIII: Sym021 Dose Level 1Experimental Treatment1 Intervention
Part 1, Sym021 monotherapy dose level 1
Group IX: Arm B: Sym021+Sym023 Dose Level 5Experimental Treatment2 Interventions
Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023
Group X: Arm B: Sym021+Sym023 Dose Level 4Experimental Treatment2 Interventions
Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023
Group XI: Arm B: Sym021+Sym023 Dose Level 3Experimental Treatment2 Interventions
Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023
Group XII: Arm B: Sym021+Sym023 Dose Level 2Experimental Treatment2 Interventions
Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023
Group XIII: Arm B: Sym021+Sym023 Dose Level 1Experimental Treatment2 Interventions
Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023
Group XIV: Arm A: Sym021+Sym022 Dose Level 4Experimental Treatment2 Interventions
Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022
Group XV: Arm A: Sym021+Sym022 Dose Level 3Experimental Treatment2 Interventions
Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022
Group XVI: Arm A: Sym021+Sym022 Dose Level 2Experimental Treatment2 Interventions
Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022
Group XVII: Arm A: Sym021+Sym022 Dose Level 1Experimental Treatment2 Interventions
Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sym022
2017
Completed Phase 1
~110
Sym023
2017
Completed Phase 1
~120
Sym021
2017
Completed Phase 1
~90

Find a Location

Who is running the clinical trial?

Symphogen A/SLead Sponsor
16 Previous Clinical Trials
761 Total Patients Enrolled
2 Trials studying Lymphoma
39 Patients Enrolled for Lymphoma
Lillian Siu, MD, FRCPCPrincipal InvestigatorPrincess Margaret Cancer Centre
3 Previous Clinical Trials
52 Total Patients Enrolled
2 Trials studying Lymphoma
39 Patients Enrolled for Lymphoma
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top